Women's bone health
- Preventative care for women 30+
- Post-pregnancy structural recovery
- Peri- & menopausal density support
- Osteopenia management
Pharmacy · Clinic · D2C
Exclusive UK distribution
Bone health, engineered
from the inside out.
Matrix Bioscience Ltd holds exclusive UK distribution rights for STEOSIL®, a clinically supported, next-generation bone-health formulation built around Mesoporosil®, a highly bioavailable silicon delivery system, plus Vitamin K2 and D3.
The hero ingredient
Meet Mesoporosil®.
380×
more soluble than conventional silicon supplements, the bioavailability behind every measurable outcome.
Conventional silicon supplements are poorly absorbed and rarely translate into measurable skeletal benefit. Mesoporosil® is a next-generation silicon delivery system, the form clinically shown to drive osteoblast activity, collagen type I synthesis and cross-linking in human cells.
Inside STEOSIL®, Mesoporosil® sits alongside Vitamin K2 (MK-7) and Vitamin D3, a synergistic triplet that supports calcium absorption, directs minerals into bone matrix, and reinforces the collagen scaffold those minerals are deposited onto.
01 / FORM
Bioavailable silicon
Delivered as orthosilicic acid, the only form clinically demonstrated to meaningfully stimulate osteoblast activity and collagen markers.
02 / ACTION
Collagen scaffold support
Stimulates type I collagen synthesis and reinforces cross-linking, the protein framework on which bone minerals are deposited.
03 / SYNERGY
Triple-active formulation
Combined with Vitamin D3 (calcium absorption) and Vitamin K2 (matrix-directed mineralisation) for measurable, additive benefit.
04 / DOSE
One tiny tablet, once a day
Designed for consumer compliance, the entire active load delivered in a single, easy-to-swallow tablet.
Clinical evidence
Science of STEOSIL®
STEOSIL® is built on the published literature for bioavailable silicon, Vitamin K2 and D3 in bone metabolism, in vitro mechanism, observational cohorts, and randomised supplementation studies.
Cell-culture · MG-63 osteoblasts
+77.6%
Collagen type I synthesis with orthosilicic acid + D3 + K2 vs. control.
Triple-active in vitro · Gu, 2022
Cell-culture · MG-63 osteoblasts
+48.4%
Osteocalcin synthesis, a key marker of new-bone formation, vs. control.
Triple-active in vitro · Gu, 2022
Fracture-healing clinical group
84.6%
Of patients achieved early removal of orthoses with silicon supplementation, vs. 15.4% control.
MR imaging study · Sildì group
Population BMD · Framingham
up to 10%
Higher hip BMD in highest vs. lowest dietary silicon quintile (men & premenopausal women).
J Bone Miner Res, 2004 · n=2,847
Mechanism summary
Collagen is the bricks.
STEOSIL® is the binder.
Collagen forms the bone framework, type I collagen alone makes up roughly 85–90% of the organic matrix. Without the right biochemical support, that scaffold cannot properly assemble, stabilise or cross-link. STEOSIL® supplies exactly that support: collagen synthesis pathways, cross-linking, mineralisation cofactors. The result is a more resilient bone matrix, not just more calcium.
Format & presentation
Tiny tablet.
Retail-ready.
STEOSIL® ships as the lead format, a small, once-daily tablet in a premium blister pack, with a soft-gel capsule available as a secondary option for partners who prefer it.
Target markets
Three high-growth
consumer segments.
Bone-health demand is no longer niche or age-gated. STEOSIL® positions cleanly across women’s preventative wellness, performance recovery, and active-longevity, in pharmacy, clinic, sports and premium e-commerce.
Sports & performance recovery
- High-impact athletes, football, rugby, run
- Stress-fracture rehab
- Return-to-play protocols
- Team & club nutrition programmes
Clubs · Performance · Specialist retail
Active lifestyle & longevity
- Healthy ageing & lifelong mobility
- Joint & bone-matrix protection
- Skeletal resilience
- Longevity & healthspan stacks
Wellness · Longevity · Subscription
Why partner
Six reasons to trade
STEOSIL® with us.
We’re the only authorised UK route to STEOSIL®. We supply premium UK brands, pharmacies, clinics and sports programmes ready to put a science-led bone health product on shelf without building it from scratch.
01
Exclusive UK rights
Sole authorised UK distributor, no parallel routes, no channel conflict, full territorial protection for committed partners.
02
Retail-ready supply
Premium blister packs, shipped shelf-ready. Minimum time-to-market, pitch deck to point-of-sale in weeks, not quarters.
03
Science-led positioning
Peer-reviewed evidence base for Mesoporosil®, K2 and D3 in bone metabolism, defensible claims, premium price point.
04
One tablet a day
Tiny, easy-to-swallow tablet, the entire daily load in a single dose. Compliance you can build subscription around.
05
Omni-channel fit
Pharmacy, clinic, sports performance, longevity D2C, one SKU sits cleanly across every premium UK channel.
06
Co-marketing support
Clinical dossier, formulation deck, claims toolkit and partner-ready brand assets, ready to plug into your marketing pipeline.
Trade enquiries
Talk to us about
distribution.
For UK retail, pharmacy, clinical, sports and D2C partners. Drop in your details and a brief outline of fit, we’ll come back within two business days with the partner pack and price tiers.
Entity
Matrix Bioscience Ltd · UK
Trade
UK only · exclusive STEOSIL®
Response
Within 2 business days
Quality
Every batch tested · CoAs on request
Frequently asked
Trade partner
questions.
If something isn’t covered here, send us an enquiry, full clinical, regulatory and supply documentation is available under NDA.
Contact us →What is STEOSIL® and what makes it different?
STEOSIL® is a next-generation bone-health supplement built around three actives: Mesoporosil® (highly bioavailable silicon delivered as orthosilicic acid), Vitamin K2 (MK-7) and Vitamin D3. Unlike most bone supplements, it doesn’t just supply calcium, it supports the collagen matrix calcium is deposited onto.
How is Mesoporosil® different from other silicon supplements?
Mesoporosil® is roughly 380× more soluble than conventional silicon supplements. Orthosilicic acid is the only form clinically demonstrated to meaningfully stimulate osteoblast activity and collagen synthesis, bioavailability is the whole story.
Are the products batch-tested? Can you provide CoAs?
Yes, every batch is independently laboratory-tested for active content, heavy metals, microbiological purity and identity. A full Certificate of Analysis (CoA) is issued per batch and supplied on request to all trade partners.
Manufacturing is conducted in EU GMP-compliant facilities with full traceability from raw material to finished pack.
What format and dosage do you ship?
Lead format is a small, easy-to-swallow tablet, one tablet, once daily, oral. Each tablet contains 100 mg Mesoporosil®, 45 µg Vitamin K2 (MK-7) and 30 µg (1200 IU) Vitamin D3. A soft-gel capsule version is available as a secondary format.
Standard pack is 30 units in a premium blister + folding carton, shelf-ready.
Is the product UK and EU regulatory compliant?
STEOSIL® is classified as a food supplement and complies with applicable UK and EU regulations including Regulation (EC) 1169/2011 on food information to consumers. Full regulatory documentation is available to trade partners under NDA.
What is the shelf life and storage requirement?
24 months from manufacture, stored in a cool dry place at no more than 25°C and out of direct sunlight.
Which channels can I distribute STEOSIL® through?
Premium pharmacy, independent pharmacy, clinic and practitioner channels, sports and performance organisations, specialist wellness retail, and D2C / e-commerce. We work with one committed partner per channel where it makes sense, talk to us about territorial fit.
How do we open a trade account?
Submit a trade enquiry via the contact form. We’ll come back within two business days with the partner pack, price tiers, lead times and the full clinical / regulatory dossier.